Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00180128
Status:
UNKNOWN
Last Update Posted:
2011-07-11
First Post:
2005-09-12
Brief Title:
AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia
Sponsor:
Technische Universität Dresden
Organization:
Technische Universität Dresden
Study Overview
Official Title:
AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic LeukemiaAPL
Status:
UNKNOWN
Status Verified Date:
2011-07
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In AIDA 2000 therapy of acute promyelocytic leukemia APL is given in a risk-adapted manner Risk factors are age and white-blood-cell WBC-count at diagnosis Induction therapy is done with ATRA and idarubicin followed by postremission therapy with daunorubicin and mitoxantrone in age adapted dosages Patients with an high WBC were additionally treated with cytarabine Finally a two year period of maintenance therapy with 6-mercaptopurine methotrexate and ATRA is performed
Detailed Description:
In AIDA 2000 therapy of acute promyelocytic leukemia APL is given in a risk-adapted manner Risk factors are age and white-blood-cell WBC-count at diagnosis Induction therapy is done with ATRA and idarubicin followed by postremission therapy with daunorubicin and mitoxantrone in age adapted dosages Patients with an high WBC were additionally treated with cytarabine Finally a two year period of maintenance therapy with 6-mercaptopurine methotrexate and ATRA is performed
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None